Teriparatide (PTH 1-34)

REQUEST QUOTATION

CAS number:
52232-67-4 (net)
99294-94-7 (acetate)

Sequence
H2N-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH

Molecular formula: C181H291N55O51S2

Molecular weight: 4117.8 a.m.u.

Fields of Application
Osteoporosis
Diagnosis of hypoparathyroidism

Description
pTH (1-34) (human) corresponds to N-terminal part of human parathyroid hormone, a peptide consisting of 84 amino acids. pTH (1-34) (human) shows the same activity and pharmacological profile as the native peptide hormone.

Teriparatide is indicated for use in postmenopausal women with osteoporosis at a high risk for fracture or with a history of osteoporotic fracture, patients with multiple risk factors for fracture, and for patients who have failed or are intolerant to other available osteoporosis therapy.

Intermittent administration of pTH (1-34) (human) acetate in low dosage stimulates bone formation and increases bone mineral density.

Administration:
Regular injectable form.

Teriparatide